JAK2-binding long noncoding RNA promotes breast cancer brain metastasis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Conventional therapies for breast cancer brain metastases (BCBMs) are limited by chemoresistance and the blood-brain barrier.
• Understanding BCBM mechanisms is crucial for developing effective treatments.

Purpose of the Study:

• To identify novel molecular drivers of BCBM.
• To investigate the role of a specific long noncoding RNA (lncRNA) in BCBM progression.
• To explore Lnc-BM as a potential therapeutic target.

Main Methods:

• Identified and named a novel lncRNA, Lnc-BM, associated with BCBM progression.
• Utilized preclinical murine models to study Lnc-BM's role in BCBM.
• Employed nanoparticle-encapsulated siRNAs to deplete Lnc-BM.
• Investigated molecular pathways including JAK2/STAT3 signaling, ICAM1, CCL2, and macrophage recruitment.

Main Results:

• Elevated Lnc-BM expression correlated with BCBM progression in patients and drove BCBM in models.
• Lnc-BM depletion effectively treated BCBM in preclinical models.
• Lnc-BM enhances JAK2 activity, promoting STAT3 phosphorylation and downstream targets (ICAM1, CCL2).
• Lnc-BM facilitates cancer cell-macrophage communication, creating a pro-metastatic microenvironment.

Conclusions:

• Lnc-BM is a key driver of BCBM by mediating breast cancer cell and brain microenvironment interactions.
• The Lnc-BM/JAK2/STAT3 pathway is critical for BCBM pathogenesis.
• Targeting Lnc-BM represents a potential therapeutic strategy for BCBM.